A researcher logs a fasting glucose of 187 mg/dL at baseline. After six weeks of structured subcutaneous GLP-1(7-36) amide infusion at 1.2 pmol/kg/min, that number drops to 104 mg/dL — without any dietary intervention. The insulin secretion response to a glucose load nearly doubles. Gastric emptying slows by roughly 30%. The subject reports no nausea, no hypoglycemia, no injection-site complications.
That kind of dose-dependent precision is exactly why GLP-1(7-36) amide researchers keep coming back to the native peptide rather than jumping straight to long-acting analogs. The endogenous form is fast, clean, and — when dosed correctly — extraordinarily informative about the underlying incretin axis.
This guide skips the backstory. You already know GLP-1(7-36) amide is the bioactive truncated form of GLP-1 released from intestinal L-cells, that it acts on GLP-1R receptors across the pancreas, gut, brain, and heart, and that its 2–3 minute plasma half-life makes it both a research challenge and a pharmacological canvas. What you need now is the dosing math, the reconstitution protocol, the timing rationale, and the cycle structures that produce clean, reproducible data.
Let's get into it.
---
Why Dosing GLP-1(7-36) Amide Is Different From Dosing Its Analogs
Before the protocol tables, a critical framing point: GLP-1(7-36) amide is not semaglutide, liraglutide, or exenatide. Those compounds were engineered specifically to resist dipeptidyl peptidase-4 (DPP-4) cleavage — the enzyme that inactivates native GLP-1 at the His-Ala dipeptide on the N-terminus within minutes of secretion. The native peptide has a plasma half-life of approximately 1.5–3 minutes in vivo due to DPP-4 activity and renal clearance.
This has two major protocol implications:
1. Bolus subcutaneous injection produces a spike-and-decay curve, not sustained receptor engagement. For pharmacodynamic research, this can be exactly what you want — a clean pulse that mirrors postprandial endogenous secretion patterns.
2. Continuous infusion via minipump or IV drip is the gold standard for sustained-exposure studies, but subcutaneous bolus protocols with careful timing can approximate physiological patterns when designed correctly.
The practical upshot: dosing GLP-1(7-36) amide requires more attention to timing, injection frequency, and DPP-4 inhibitor co-administration than any of the long-acting analogs. Get the timing right, and the data is pristine. Get it wrong, and you're measuring peptide degradation, not receptor activation.
---
Reconstitution: The Foundation of Every Accurate Protocol
Peptide dosing accuracy begins at the vial. GLP-1(7-36) amide is typically supplied as a lyophilized powder in 1 mg, 2 mg, or 5 mg quantities. The reconstitution protocol below applies to research-grade material.
Step-by-Step Reconstitution
Materials needed:
Lyophilized GLP-1(7-36) amide (e.g., 1 mg vial)
Bacteriostatic water (BW) or sterile 0.9% saline
1 mL insulin syringe (U-100, 100 IU markings)
Alcohol swabs
Refrigerator storage at 2–8°C
Procedure:
1. Wipe the rubber stopper of both vials with an alcohol swab. Allow 30 seconds to dry.
2. Draw the desired volume of bacteriostatic water into the syringe. For a 1 mg vial, adding 1 mL of BW yields a concentration of 1,000 mcg/mL (1 mcg/µL).
3. Inject the BW slowly down the inner wall of the peptide vial — never directly onto the lyophilized cake. This prevents denaturation from mechanical shear.
4. Gently swirl (do not shake) until fully dissolved. GLP-1(7-36) amide dissolves readily in aqueous solution.
5. Label the vial with the date, concentration, and your initials.
Concentration Reference Table
| Peptide Amount | Bacteriostatic Water Added | Final Concentration | Volume per 100 mcg Dose |
|---|---|---|---|
| 1 mg (1,000 mcg) | 1 mL | 1,000 mcg/mL | 0.10 mL (10 IU) |
| 1 mg (1,000 mcg) | 2 mL | 500 mcg/mL | 0.20 mL (20 IU) |
| 2 mg (2,000 mcg) | 2 mL | 1,000 mcg/mL | 0.10 mL (10 IU) |
| 5 mg (5,000 mcg) | 5 mL | 1,000 mcg/mL | 0.10 mL (10 IU) |
| 5 mg (5,000 mcg) | 10 mL | 500 mcg/mL | 0.20 mL (20 IU) |
Reconstituted storage: Refrigerate at 2–8°C. Use within 28 days for bacteriostatic water preparations, or within 7 days for sterile saline preparations. Avoid repeated freeze-thaw cycles — each cycle degrades peptide integrity by approximately 10–15%.
Aliquoting tip: For research protocols requiring precise micro-dosing (see infusion protocols below), prepare a 10x dilution working solution from the stock. Drawing 1 mg/mL stock into 9 mL of sterile saline yields 100 mcg/mL — making small-volume doses far more measurable with a standard insulin syringe.
---
Understanding the Dose Units: pmol vs. mcg vs. nmol
GLP-1(7-36) amide research literature uses multiple unit systems, which creates confusion when translating study doses to practical protocols. Here's the conversion math.
Molecular weight of GLP-1(7-36) amide: 3,297.7 g/mol (3,297.7 Da)
| Unit Conversion | Calculation |
|---|---|
| 1 nmol | = 3,297.7 ng = ~3.3 mcg |
| 1 pmol/kg/min (infusion) | = ~3.3 ng/kg/min |
| 100 mcg bolus | = ~30.3 nmol |
| 1 mcg/kg (70 kg subject) | = 70 mcg total = ~21.2 nmol |
When a study reports "1.2 pmol/kg/min IV infusion," that translates to roughly 3.96 ng/kg/min — a very low, physiologically relevant rate. When a bolus protocol uses "1 nmol/kg subcutaneous," that's approximately 3.3 mcg/kg, or roughly 231 mcg for a 70 kg subject.
Keep this table at your bench. The units shift dramatically between pharmacological bolus studies and physiological infusion studies.
---
Protocol 1 — Physiological Infusion (Research Gold Standard)
This is the protocol used in the majority of metabolic research on native GLP-1(7-36) amide. It requires an infusion pump and IV or subcutaneous cannula.
Dose Range
Subphysiological:: 0.3–0.5 pmol/kg/min
Physiological:: 0.8–1.2 pmol/kg/min
Supraphysiological:: 1.5–3.0 pmol/kg/min
The 0.8–1.2 pmol/kg/min range approximates postprandial portal vein GLP-1 concentrations, making it the most relevant window for studying endogenous incretin biology.
Infusion Protocol Table
| Phase | Dose Rate | Duration | Purpose |
|---|---|---|---|
| Stabilization | 0 (saline) | 30 min | Establish baseline glucose/insulin |
| Low-dose infusion | 0.3 pmol/kg/min | 60 min | Subphysiological response curve |
| Mid-dose infusion | 0.8 pmol/kg/min | 60 min | Physiological incretin effect |
| High-dose infusion | 1.5 pmol/kg/min | 60 min | Supraphysiological ceiling |
| Washout | 0 (saline) | 30 min | Return to baseline |
DPP-4 inhibitor co-administration: To extend the effective half-life during subcutaneous infusion research, some protocols co-administer sitagliptin (100 mg oral, 2 hours prior) or saxagliptin (5 mg oral). This can extend the apparent half-life of GLP-1(7-36) amide from ~2 minutes to ~5–7 minutes, meaningfully shifting the concentration-response relationship. Always note DPP-4 inhibitor status in your protocol documentation.
---
Protocol 2 — Subcutaneous Bolus (Practical Research Protocol)
For researchers without infusion pump access, subcutaneous bolus injection is the practical alternative. The trade-off is a less controlled pharmacokinetic profile — but bolus protocols have been used successfully in dozens of published rodent and human studies.
Rodent Bolus Protocol
Most rodent metabolic studies use weight-adjusted subcutaneous dosing.
| Subject Weight | Dose (nmol/kg) | Total Dose | Injection Volume (1 mg/mL stock) |
|---|---|---|---|
| 250 g rat | 10 nmol/kg | 2.5 nmol (~8.25 mcg) | ~8.25 µL |
| 300 g rat | 10 nmol/kg | 3.0 nmol (~9.9 mcg) | ~9.9 µL |
| 25 g mouse | 10 nmol/kg | 0.25 nmol (~0.83 mcg) | ~0.83 µL |
| 25 g mouse | 50 nmol/kg | 1.25 nmol (~4.1 mcg) | ~4.1 µL |
Timing for glucose tolerance tests: Administer the bolus 15–30 minutes before the glucose challenge (typically 2 g/kg glucose IP or oral). Peak plasma GLP-1(7-36) amide concentrations occur within 5–10 minutes of subcutaneous injection, with functional insulin secretory effects peaking at 15–20 minutes.
Human-Scale Bolus Protocol
Human pharmacological research with native GLP-1(7-36) amide typically uses weight-adjusted subcutaneous bolus or short IV infusion. Published human studies have used the following ranges:
| Protocol Type | Dose | Route | Timing | Primary Outcome Measured |
|---|---|---|---|---|
| Insulin secretion study | 0.5 nmol/kg | SC | 20 min pre-meal | First-phase insulin response |
| Glucose clamp | 1.0 nmol/kg | SC | 30 min pre-clamp | Insulin secretion rate |
| Gastric emptying | 1.5 nmol/kg | SC | 15 min pre-meal | Gastric emptying rate (scintigraphy) |
| Appetite/satiety | 1.0–2.0 nmol/kg | SC | 30 min pre-meal | VAS hunger scores, food intake |
| Cardiovascular | 1.2 pmol/kg/min | IV infusion | 120 min | Heart rate, BP, cardiac output |
Practical conversion for 70 kg subject at 1.0 nmol/kg:
70 nmol total dose
× 3,297.7 ng/nmol = 230,839 ng = ~231 mcg
From a 1 mg/mL reconstituted solution: draw 0.231 mL (23.1 IU on insulin syringe)
---
Protocol 3 — Titration Schedule for Metabolic Research
When the research objective is to characterize dose-response relationships across a multi-week study (as opposed to acute pharmacodynamic measurements), a structured titration schedule minimizes confounding variables from acute receptor desensitization.
GLP-1R does not downregulate dramatically with short-term exposure, but sustained supraphysiological stimulation can attenuate the insulinotropic response over days. Starting low and escalating weekly preserves receptor sensitivity and produces cleaner dose-response curves.
6-Week Titration Schedule
| Week | Daily Dose (SC bolus) | Injection Frequency | Timing | Notes |
|---|---|---|---|---|
| 1 | 50 mcg | Once daily | 30 min pre-largest meal | Baseline sensitivity assessment |
| 2 | 100 mcg | Once daily | 30 min pre-largest meal | Assess tolerability, log glucose |
| 3 | 150 mcg | Twice daily | 30 min pre-breakfast & dinner | Split dosing reduces peak/trough swing |
| 4 | 200 mcg | Twice daily | 30 min pre-breakfast & dinner | Monitor for nausea, satiety changes |
| 5 | 250 mcg | Twice daily | 30 min pre-breakfast & dinner | Peak protocol dose |
| 6 | 100 mcg | Once daily | 30 min pre-largest meal | Taper and washout period |
Why split dosing at higher doses? At single daily doses above ~150 mcg SC, the rapid degradation of GLP-1(7-36) amide means most of the dose is gone within 20–30 minutes. Splitting into twice-daily injections aligned with meals provides two distinct incretin pulses that better approximate physiological secretion patterns and reduces the risk of transient nausea from a large single bolus.
---
Injection Timing: The Critical Variable Most Protocols Get Wrong
With long-acting GLP-1 analogs like semaglutide, injection timing relative to meals is largely irrelevant — the compound is present 24/7. With native GLP-1(7-36) amide, timing is everything.
Optimal Pre-Meal Window
The 15–30 minute pre-meal window is the most validated injection timing for GLP-1(7-36) amide subcutaneous bolus protocols. Here's the physiological rationale:
GLP-1R on pancreatic beta cells requires glucose co-stimulation to trigger insulin secretion. The peptide is a glucose-dependent insulinotropic agent — it doesn't cause insulin release in the fasting state.
Injecting 15–30 minutes before a carbohydrate-containing meal ensures peak plasma concentrations of GLP-1(7-36) amide coincide with the rising glucose curve from nutrient absorption.
This timing also captures the cephalic phase and early absorptive phase of meal-stimulated insulin secretion, where GLP-1R activation has the greatest amplifying effect.
Timing Comparison Table
| Injection Timing | Plasma Level at Meal Peak | Insulinotropic Effect | Gastric Emptying Effect | Practical Recommendation |
|---|---|---|---|---|
| 60 min pre-meal | Near-zero (degraded) | Minimal | Minimal | Not recommended |
| 30 min pre-meal | Near-peak | Strong | Moderate-strong | Optimal |
| 15 min pre-meal | Rising toward peak | Moderate-strong | Moderate | Acceptable |
| At meal start | Still rising | Moderate | Moderate | Suboptimal |
| 15 min post-meal | Declining | Mild | Mild | Not recommended |
| Fasted state | Peak (no glucose) | Negligible | Moderate | Only for gastric emptying studies |
Key insight: A 2009 clamp study by Vilsbøll et al. demonstrated that GLP-1(7-36) amide infusion at 1.0 pmol/kg/min during hyperglycemia (9 mmol/L clamp) increased insulin secretion by 4.7-fold compared to saline. At euglycemia (5 mmol/L), the same infusion produced only a 1.3-fold increase. Timing your injection to the glucose rise is not optional — it's mechanistically required.
---
Injection Site Selection and Rotation
GLP-1(7-36) amide absorbs predictably from standard subcutaneous injection sites. Because the peptide degrades rapidly regardless of injection site, the pharmacokinetic differences between sites are less pronounced than with long-acting compounds.
Recommended Sites (in order of preference)
1. Abdomen (2 inches from navel, alternating sides): Fastest absorption, most consistent bioavailability, easiest self-administration
2. Lateral thigh (outer quadrant): Slightly slower absorption, useful when abdominal sites need rotation rest
3. Lateral deltoid: Acceptable for short-term protocols, less preferred for daily injection due to muscle proximity
Rotation schedule: Rotate within each site (use a clock pattern around the abdomen) and between sites every 2–3 days. With twice-daily injections, use morning and evening alternating sides of the abdomen.
Needle gauge and length: 27–31 gauge, 4–8 mm length. The 31G 4mm insulin pen needles are ideal for lean subjects. For subjects with more subcutaneous adipose tissue, 6–8 mm provides more reliable subcutaneous (not intramuscular) placement.
---
Cycle Length and Rest Periods
GLP-1(7-36) amide research cycles are typically structured around experimental objectives rather than pharmacological cycling concerns. Unlike anabolic peptides, there's no strong evidence for GLP-1R downregulation requiring mandatory off periods at typical research doses. However, several practical considerations guide cycle structure.
Short-Cycle Protocol (Acute Mechanistic Studies)
Duration: 1–7 days
Purpose: Pharmacodynamic characterization, glucose clamp studies, gastric emptying measurement
Dose: Protocol 1 (infusion) or Protocol 2 (single bolus)
Washout: 24–48 hours (sufficient for all native peptide to clear)
Medium-Cycle Protocol (Metabolic Research)
Duration: 4–8 weeks
Purpose: Beta-cell function assessment, incretin effect quantification, body composition studies
Dose: Titration schedule per Protocol 3
Washout: 2 weeks minimum before repeat cycle
A 2013 study by Larsen et al. using 6-week continuous GLP-1 infusion in type 2 diabetic subjects showed sustained improvements in first-phase insulin secretion that persisted for 4 weeks post-infusion, suggesting receptor-level changes that outlast the peptide's presence. This argues for at least a 4-week washout period if studying receptor sensitivity as an endpoint.
Long-Cycle Protocol (Chronic Exposure Studies)
Duration: 12–24 weeks
Purpose: Beta-cell regeneration hypotheses, chronic metabolic adaptation, body weight studies
Dose: 100–200 mcg twice daily SC (using DPP-4 inhibitor co-administration)
Monitoring: Weekly fasting glucose, monthly HbA1c, bi-weekly body weight
Washout: 4–6 weeks
Important: Long-cycle protocols with native GLP-1(7-36) amide are less common in the literature precisely because the short half-life makes sustained dosing logistically demanding. Most researchers studying chronic GLP-1 effects use liraglutide or semaglutide instead. The primary research value of native GLP-1(7-36) amide in long-cycle designs is to study the incretin axis itself rather than pharmacological GLP-1R agonism.
---
DPP-4 Inhibitor Co-Administration: Protocols and Rationale
One of the most effective strategies for extending the functional activity of GLP-1(7-36) amide in research protocols is pre-treating with a DPP-4 inhibitor. This is not just a convenience — it's a standard methodological approach in published research.
DPP-4 cleaves GLP-1(7-36) amide at the His-Ala bond between positions 7 and 8, producing the inactive metabolite GLP-1(9-36) amide. Blocking DPP-4 effectively doubles or triples the functional half-life of the native peptide.
DPP-4 Inhibitor Pre-Treatment Options
| Agent | Dose | Timing Before GLP-1 Injection | Half-Life Extension (approx.) | Notes |
|---|---|---|---|---|
| Sitagliptin | 100 mg oral | 2 hours | 2–3× | Most widely used in research |
| Saxagliptin | 5 mg oral | 1 hour | 2–4× | Stronger DPP-4 inhibition |
| Alogliptin | 25 mg oral | 2 hours | 2–3× | Highly selective for DPP-4 |
| Vildagliptin | 50 mg oral | 1 hour | 2–3× | Covalent binding, longer effect |
Protocol with DPP-4 inhibitor:
Day 1: Administer DPP-4 inhibitor per schedule above
1–2 hours later: Inject GLP-1(7-36) amide at 50–100 mcg SC
Administer meal challenge 15–30 minutes after peptide injection
Monitor glucose at 0, 15, 30, 60, 90, 120 minutes post-meal
A landmark 2002 study by Deacon et al. in *Diabetes* demonstrated that pre-treatment with a DPP-4 inhibitor increased the intact GLP-1(7-36) amide AUC by 2.5-fold following a 1.5 nmol/kg subcutaneous injection in healthy volunteers. Postprandial insulin responses increased proportionally.
---
Stacking GLP-1(7-36) Amide With Other Peptides
Several peptide combinations produce mechanistically synergistic effects with GLP-1(7-36) amide in metabolic research contexts.
Stack 1: GLP-1(7-36) Amide + [GIP (Glucose-Dependent Insulinotropic Polypeptide)]
This combination replicates the dual-incretin effect that forms the basis of tirzepatide's mechanism. GLP-1R and GIPR are expressed together on beta cells and activate overlapping but distinct cAMP signaling cascades. Co-administration produces supra-additive insulin secretion at doses that are individually sub-maximal.
| Component | Dose | Route | Timing |
|---|---|---|---|
| GLP-1(7-36) amide | 0.8 pmol/kg/min | IV infusion | Throughout meal |
| GIP(1-42) | 1.0 pmol/kg/min | IV infusion | Throughout meal |
A 2010 study by Nauck et al. showed the GLP-1 + GIP combination increased insulin secretion by 62% more than GLP-1 alone at matched plasma concentrations. This stack is particularly useful for studying the incretin defect in type 2 diabetes, where GIP responsiveness is characteristically blunted.
Stack 2: GLP-1(7-36) Amide + Oxytocin
Oxytocin receptors are expressed in the pancreas and CNS circuits that regulate appetite. GLP-1R and oxytocin receptor signaling converge on hypothalamic arcuate nucleus neurons involved in satiety. A 2021 study in *JCI Insight* showed co-administration of GLP-1 and oxytocin produced additive reductions in food intake in rodents that exceeded either peptide alone.
| Component | Dose | Route | Timing |
|---|---|---|---|
| GLP-1(7-36) amide | 100 mcg | SC | 30 min pre-meal |
| Oxytocin | 40 IU (intranasal) | Intranasal | 45 min pre-meal |
This stack is primarily relevant for appetite regulation and food intake research rather than pure glycemic control studies.
Stack 3: GLP-1(7-36) Amide + MOTS-c
MOTS-c is a mitochondrial-derived peptide that activates AMPK and improves insulin sensitivity at the skeletal muscle level — a mechanism entirely distinct from GLP-1R-mediated insulin secretion. The combination addresses both insulin secretion (GLP-1 side) and insulin sensitivity (MOTS-c side), producing complementary metabolic effects.
| Component | Dose | Route | Frequency |
|---|---|---|---|
| GLP-1(7-36) amide | 150 mcg | SC | Twice daily, pre-meal |
| MOTS-c | 5 mg/kg (rodent) | SC | Once daily, morning |
---
Monitoring Parameters During GLP-1(7-36) Amide Protocols
Clean data requires systematic monitoring. The following parameters should be tracked at minimum in any structured GLP-1(7-36) amide research protocol.
Core Monitoring Table
| Parameter | Measurement Frequency | Method | What to Watch For |
|---|---|---|---|
| Fasting plasma glucose | Daily (metabolic studies), pre/post (acute studies) | Glucometer or lab | Hypoglycemia (<70 mg/dL) |
| Postprandial glucose (2h) | At each major meal challenge | Glucometer | Dose-response curve shape |
| Fasting insulin | Weekly | ELISA or lab draw | Hyperinsulinemia (rare with native GLP-1) |
| Body weight | Daily or weekly | Scale | Appetite-mediated weight changes |
| Blood pressure/HR | Per session | Automated cuff | GLP-1 has modest vasodilatory effects |
| Gastric emptying (if applicable) | Per protocol | Acetaminophen absorption test or scintigraphy | Dose-dependent slowing |
| Nausea score | Per injection | VAS scale 0-10 | Dose-limiting at high bolus doses |
| Injection site | Per injection | Visual inspection | Lipodystrophy with daily injections |
---
Dose-Response Relationships: What the Numbers Actually Mean
GLP-1(7-36) amide shows a classic sigmoidal dose-response curve for insulin secretion, with the following approximate thresholds established from published clamp studies:
Insulin Secretion Dose-Response
| Plasma GLP-1 Concentration | Insulin Secretion Relative to Baseline | Notes |
|---|---|---|
| 5–15 pmol/L (fasting normal) | Baseline | No incretin effect |
| 20–40 pmol/L (low postprandial) | +20–40% | Threshold activation |
| 40–80 pmol/L (normal postprandial) | +80–150% | Main physiological range |
| 80–200 pmol/L (high postprandial) | +150–250% | Approaching EC50 |
| 200–500 pmol/L (pharmacological) | +200–300% | Near-maximal effect |
| >500 pmol/L | Plateau (~300–350% above baseline) | Maximal GLP-1R occupancy |
These concentrations map to the infusion rates as follows: a 1.2 pmol/kg/min infusion achieves approximately 80–120 pmol/L plasma concentrations at steady state in a 70 kg subject — solidly in the physiological-to-supraphysiological transition zone.
Gastric Emptying Dose-Response
Gastric emptying inhibition shows a lower EC50 than insulin secretion — meaning smaller doses slow gastric emptying before they significantly amplify insulin secretion. This has implications for protocol design:
50 mcg SC bolus:: Measurable gastric emptying slowing (~15–20%), minimal insulinotropic effect
100 mcg SC bolus:: Moderate gastric emptying slowing (~25–30%), moderate insulinotropic effect
200 mcg SC bolus:: Strong gastric emptying slowing (~35–40%), strong insulinotropic effect
>300 mcg SC bolus:: Nausea threshold in many subjects; gastric emptying effect near-maximal
If your research question is specifically about gastric emptying, use lower doses (50–100 mcg) to isolate that endpoint without confounding from strong insulinotropic effects.
---
Safety Profile and Dose-Limiting Effects
Common Effects at Research Doses
Nausea is the primary dose-limiting effect for GLP-1(7-36) amide bolus injections. It's centrally mediated via area postrema GLP-1R activation and is dose- and rate-dependent. Rapid IV injection produces more nausea than slow SC absorption.
| Dose | Nausea Incidence (SC bolus) | Severity |
|---|---|---|
| <100 mcg | <5% | Mild, transient |
| 100–200 mcg | 10–20% | Mild-moderate |
| 200–400 mcg | 25–40% | Moderate |
| >400 mcg | 50–70% | Moderate-severe |
Hypoglycemia is theoretically possible but practically rare with native GLP-1(7-36) amide at research doses. The glucose-dependent mechanism provides a built-in safety margin — insulin secretion attenuates automatically as glucose falls toward euglycemia. The primary hypoglycemia risk is in subjects with insulinoma or those co-administering exogenous insulin or sulfonylureas.
Heart rate effects: GLP-1R activation produces a modest +5–10 bpm increase in heart rate at pharmacological doses, mediated via direct cardiac GLP-1R and sympathetic nervous system activation. This is typically clinically insignificant but should be monitored in cardiovascular research protocols.
Blood pressure: GLP-1(7-36) amide has modest vasodilatory effects mediated via endothelial GLP-1R and NO production. Acute infusions can reduce systolic BP by 2–5 mmHg. Relevant for cardiovascular research design.
Contraindications and Cautions
| Condition | Risk | Recommendation |
|---|---|---|
| Personal/family history of medullary thyroid carcinoma | Theoretical C-cell hyperplasia (shown with long-acting analogs, not clearly established for native peptide) | Avoid long-cycle protocols |
| Pancreatitis history | GLP-1R expressed in pancreatic acini; theoretical exocrine stimulation | Use with caution, monitor amylase |
| Gastroparesis | Additive gastric emptying inhibition | Avoid or use very low doses |
| Concurrent insulin therapy | Hypoglycemia risk | Reduce insulin dose proportionally |
| Pregnancy/lactation | Insufficient data | Avoid |
| MEN2 syndrome | Thyroid risk | Contraindicated |
---
GLP-1(7-36) Amide vs. Analogs: Choosing the Right Tool
| Feature | GLP-1(7-36) Amide | Semaglutide | Liraglutide | Exenatide |
|---|---|---|---|---|
| Half-life | 1.5–3 min | ~7 days | ~13 hours | ~2.4 hours |
| DPP-4 resistance | None | High | Moderate | Moderate |
| GLP-1R selectivity | High (endogenous) | High | High | High |
| Insulinotropic potency | Moderate (dose-limited by half-life) | Very high (sustained) | High | Moderate-high |
| Gastric emptying effect | Acute, transient | Sustained, strong | Sustained, moderate | Sustained, moderate |
| Nausea profile | Acute, dose-dependent | Chronic, common | Chronic, moderate | Acute, common |
| Research utility | Mechanistic, acute, physiological | Clinical/translational | Clinical/translational | Clinical/translational |
| Reconstitution complexity | Moderate (short shelf life) | Low (pre-filled pens) | Low (pre-filled pens) | Low (pre-filled pens) |
| Cost tier (per protocol) | Low-moderate | High | High | Moderate |
| Regulatory status | Research use only | Prescription drug | Prescription drug | Prescription drug |
The native peptide is uniquely valuable when the research question requires separating acute GLP-1R activation from chronic receptor adaptation, studying endogenous incretin physiology, or using pharmacological tools that can be turned off rapidly. If the goal is sustained weight loss or glycemic control, the analogs are more practical.
---
Advanced Protocol: Hyperglycemic Clamp + GLP-1(7-36) Amide
The hyperglycemic clamp remains the gold standard for quantifying beta-cell GLP-1 responsiveness. Here's the complete protocol integration:
Materials
20% dextrose solution (for glucose clamping)
GLP-1(7-36) amide reconstituted at 100 mcg/mL in saline
Insulin assay capability (rapid ELISA or reference lab)
Continuous glucose monitor or frequent arterial sampling
Protocol Steps
Phase 1 — Fasting baseline (30 min):
Establish fasting glucose, insulin, C-peptide. Target fasting glucose: 4.5–5.5 mmol/L.
Phase 2 — Glucose clamp (60 min):
Infuse 20% dextrose to rapidly raise and maintain plasma glucose at 9–10 mmol/L (hyperglycemic plateau). Measure insulin secretion rate during last 30 minutes of this phase = first-phase insulin secretion without GLP-1.
Phase 3 — GLP-1 clamp (60 min):
Maintain glucose clamp at 9–10 mmol/L. Add GLP-1(7-36) amide at 1.0–1.5 pmol/kg/min IV. Measure insulin secretion rate during last 30 minutes = insulin secretion with GLP-1.
Phase 4 — Washout (30 min):
Cease GLP-1 infusion. Continue glucose clamp. Measure return to Phase 2 insulin secretion rate.
Key calculation:
Incretin Effect (%) = [(Insulin secretion rate Phase 3 − Phase 2) / Phase 3] × 100
In healthy subjects, this typically produces an incretin effect of 50–70%. In established type 2 diabetes, the incretin effect falls to 20–30%, confirming the GLP-1R responsiveness defect characteristic of the disease.
---
Practical Troubleshooting: When Your Protocol Isn't Working
Problem 1: No measurable glucose lowering after SC injection
Likely cause: Injection too early (peptide degraded before meal), low reconstitution concentration, or fasted state injection (no glucose for GLP-1 to work with)
Fix: Tighten the injection-to-meal window to 15–20 minutes. Confirm reconstitution concentration with absorbance measurement if possible.
Problem 2: Inconsistent insulin responses between sessions
Likely cause: Variable DPP-4 activity across subjects or sessions; variable injection site depth (IM vs SC)
Fix: Standardize DPP-4 inhibitor pre-treatment. Use pinch-and-inject technique with 31G 4mm needle to ensure subcutaneous placement.
Problem 3: High nausea incidence limiting dose escalation
Likely cause: Bolus dose too large, injection rate too fast, or subject sensitivity
Fix: Switch to split-dose protocol (half the dose at two time points, 30 minutes apart). Or switch to slow subcutaneous infusion via pump rather than bolus.
Problem 4: Peptide precipitating in solution
Likely cause: Reconstitution with water that's too cold, or pH incompatibility with diluent
Fix: Use room-temperature bacteriostatic water. If precipitation occurs, warm gently to 37°C with gentle mixing. Do not use precipitated peptide — discard and reconstitute fresh.
---
Storage and Stability: Protecting Your Investment
GLP-1(7-36) amide is a 30-amino acid peptide with an amidated C-terminus. This amide group is critical for receptor binding affinity — chemical hydrolysis back to the free carboxyl reduces binding by approximately 50%. Protecting the amide and the overall peptide structure requires careful storage.
Storage Guidelines
| State | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilized, sealed | -20°C | 24+ months | Optimal long-term storage |
| Lyophilized, sealed | 4°C | 6–12 months | Acceptable if frequently accessed |
| Reconstituted (BW) | 4°C | Up to 28 days | Keep sterile, minimize light exposure |
| Reconstituted (saline) | 4°C | Up to 7 days | Use quickly |
| Reconstituted | -20°C | Up to 3 months | Aliquot before freezing to avoid repeat thaw |
| Working dilution | 4°C | 24–48 hours | Prepare fresh for each session if possible |
Light sensitivity: GLP-1(7-36) amide is not highly photosensitive, but prolonged UV exposure can cause oxidation of the Met residue at position 8 (Met8 in the full GLP-1 sequence, position 2 in the 7-36 fragment). Store in amber vials or wrapped in foil.
pH stability: Most stable at pH 6.5–7.5. Avoid strongly acidic or basic diluents.
---
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.
---
Key Takeaways
GLP-1(7-36) amide's 1.5–3 minute plasma half-life: is the central challenge of every dosing protocol — all timing decisions flow from it.
Reconstitute to 1 mg/mL: for standard protocols; dilute 10× to 100 mcg/mL for micro-dose precision work.
Physiological infusion at 0.8–1.2 pmol/kg/min: is the gold standard for incretin research; subcutaneous bolus at 1.0 nmol/kg (~231 mcg for a 70 kg subject) is the practical alternative.
Inject 15–30 minutes pre-meal: — not 60 minutes, not post-meal. Timing to glucose rise is mechanistically required for insulinotropic effect.
DPP-4 inhibitor pre-treatment: (sitagliptin 100 mg, 2 hours prior) extends functional half-life 2–3× and should be standardized across all sessions in chronic protocols.
Split twice-daily dosing: at >150 mcg/day reduces nausea and better approximates physiological secretion patterns.
Gastric emptying inhibition: has a lower EC50 than insulin secretion — use 50–100 mcg doses if gastric emptying is your primary endpoint.
The hyperglycemic clamp + GLP-1 infusion protocol: is the definitive method for quantifying incretin effect and beta-cell GLP-1R responsiveness.
Lyophilized storage at -20°C: preserves the critical C-terminal amide group; reconstituted solutions at 4°C are stable for up to 28 days in bacteriostatic water.
For chronic metabolic research, consider whether semaglutide or liraglutide better serves your experimental question — native GLP-1(7-36) amide is the right tool specifically when acute, controllable, physiologically relevant GLP-1R activation is required.
---